By targeting β-catenin, β-TRCP1 plays a negative role in regulating the Wnt pathway, partially explaining how somatic mutations in β-TRCP1/2 preventing their E3 ligase activity identified in human gastric cancer correlated with stabilization of β-catenin in these tissues and development of tumors (Saitoh and Katoh, 2001). The gene discussed is BTRC; the disease is gastric cancer.